Lakeland PeptidesPeptide therapy, explained · Lakeland & Polk County, FL

Goal

Peptides for Weight Loss: A Plain-Language Guide for Lakeland

Not reviewed by a licensed provider. Read our disclaimer

Last updated

Weight loss is the most common reason people in Lakeland and the rest of Polk County ask about peptides. This page explains which medicines are involved, how strong the evidence is for each, and what to ask before you start. It is general information, not advice for your situation.

Overview

When people talk about “peptides for weight loss,” they usually mean prescription medicines that copy gut hormones involved in appetite and blood sugar. The best known are GLP-1 receptor agonists such as semaglutide. These act like GLP-1, a hormone your gut releases after you eat, and help reduce appetite.

These medicines are very different from many products marketed as “peptides” at wellness clinics or online. Several have been tested in large, randomized, placebo-controlled trials. (Randomized means people were assigned by chance; placebo-controlled means one group got a dummy treatment for comparison.) Some are FDA-approved for long-term weight management in certain adults.12

Other peptides are also promoted for fat loss. Most of them have little or no good human research behind them. The list below covers both groups, so you can see the difference.

Peptides used for weight loss

FDA-approved for weight management

  • Semaglutide (FDA-approved, large trials). Sold for weight management as Wegovy. In a 68-week trial of 1,961 adults, people on weekly semaglutide plus diet and activity counseling lost 14.9% of their body weight on average, compared with 2.4% on placebo.3 Wegovy is also approved to lower the risk of heart attack and stroke in certain adults with heart disease.1
  • Tirzepatide (FDA-approved, large trials). Sold for weight management as Zepbound. It acts on two hormone receptors, GLP-1 and GIP. In a 72-week trial paid for by its maker, adults without diabetes lost about 15% to 21% of their weight on average, depending on dose, compared with about 3% on placebo.4 Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.2
  • Liraglutide (FDA-approved, large trials). An older GLP-1 medicine given as a daily injection, sold for weight management as Saxenda.5 In a one-year trial, people on liraglutide plus lifestyle counseling lost about 8.4 kg on average, compared with 2.8 kg on placebo.6 That is less than in the separate semaglutide and tirzepatide trials, though those were not head-to-head comparisons.

Approved for one narrow use only

  • Tesamorelin (FDA-approved for one use). Its only approved use is reducing excess belly fat in adults with HIV-related lipodystrophy. Its label says it is not for weight loss. In trials, deep belly fat fell compared with placebo, but body weight did not change.7

Not approved: experimental or unproven

  • Retatrutide (some human trials; not approved). An experimental weekly shot that acts on three hormone receptors. In an 80-week trial of 2,339 adults with obesity, paid for by its maker, average weight loss was 17.6% to 25.0% depending on dose, compared with 3.9% on placebo.8 It is not FDA-approved. In August 2026, FDA warned a Florida online seller that its retatrutide product was an unapproved new drug.9
  • AOD-9604 (some human trials, which were negative). A piece of growth hormone developed as a weight-loss drug. Its largest trial, in 502 adults, did not show weight loss, and FDA concluded there is “a lack of evidence to support the effectiveness” of AOD-9604 for obesity.10
  • MOTS-c (animal and lab data only). A peptide made by the body’s mitochondria. It has been studied in mice. FDA found no studies that gave it to people, and says its risks in humans are unknown.11

Our guide to compounded vs. FDA-approved peptides explains why approval status matters.

What to realistically expect

Trial results are averages. Some people lose a lot of weight, some lose less, and a few respond very little. A few other things are worth knowing.

  • Weight loss in trials came with lifestyle support. In the semaglutide trial, everyone also got diet and activity counseling.3 The medicine was an addition to those habits, not a replacement.
  • Weight usually returns after stopping. In a follow-up of the semaglutide trial, people who stopped the drug and the lifestyle program regained about two-thirds of the weight they had lost within a year.12 On average, people also regained weight after stopping tirzepatide. One analysis that pooled semaglutide and tirzepatide studies projected that about half of the lost weight would return within about 7.5 months. That figure is a model estimate.13 Talk with a provider about the long-term plan before you begin.
  • Muscle is a real question. Some of the weight lost on GLP-1 medicines is lean mass, not just fat. Studies disagree on how much: from about 15% to as much as 40% to 60% of the weight lost. Part of what scans count as “lean mass” is water, organs and bone, not just muscle.14 Older adults may need extra care.14 Ask a provider about protein and strength training.
  • Cost adds up over time. As of November 12, 2026, the makers of Wegovy and Zepbound listed cash prices from $149 to $699 a month, depending on the drug, dose and refill timing.1516 Offers can change. From July 2026 through 2027, a temporary Medicare program lets eligible people with Part D drug coverage get certain GLP-1 weight-loss drugs for a $50 copay.17 Our insurance and HSA/FSA guide and cost guide explain more. Clinic programs may add visit, lab or membership fees on top of the drug. Ask any provider for a written price breakdown before you start.

If a clinic promises a specific number of pounds by a specific date, treat that as a warning sign.

Safety considerations

  • Stomach side effects are common. In semaglutide’s trials, nausea affected 44% of people, compared with 16% on placebo. Diarrhea, vomiting and constipation were also common.1 With tirzepatide, these were most common while the dose was being raised.2
  • Boxed warning. Semaglutide and tirzepatide caused thyroid tumors in rodents. Whether this happens in humans is unknown. They should not be used by people with a personal or family history of medullary thyroid cancer or a condition called MEN 2.12
  • Other label warnings include pancreatitis, gallbladder problems, kidney injury from dehydration, serious allergic reactions, low blood sugar when combined with insulin or certain diabetes pills, and a risk of inhaling stomach contents during anesthesia.2 Tell any surgeon or anesthesia team that you take one.
  • Pregnancy and birth control. Tirzepatide may harm a pregnancy, and birth-control pills may work less reliably after starting it and after each dose increase.2
  • Tesamorelin can raise IGF-1 (a growth-related hormone) above the normal range and raise blood sugar.7
  • Compounded versions. The national shortages that allowed wide compounding have ended. FDA declared the tirzepatide shortage over in December 2024, after re-evaluating an October 2024 decision, and the semaglutide shortage over in February 2025. Compounding grace periods ended in early 2025.18 FDA has received reports of side effects with compounded GLP-1 drugs, including dosing mistakes.19 If a compounded product is offered, ask which licensed pharmacy makes it and how doses are measured.
  • “Research use only” products. FDA says a “research use only” label does not make it legal to sell a drug meant for people.9 See our guide to research-chemical peptide risks.

Seek medical care right away for severe stomach pain, signs of dehydration, or any symptom that worries you.

Questions to ask a provider

  • Am I a good candidate for a GLP-1 medicine, given my health history and current medicines?
  • Why would you choose this medicine for me, and what evidence supports it?
  • Is this a brand-name product or a compounded version? If compounded, which licensed pharmacy makes it?
  • What lab work do you need before and during treatment?
  • How will we protect muscle, and track progress besides the scale?
  • What should I do if I have side effects, and how do I reach you?
  • What is the plan if I want to stop, or if I reach my goal?
  • What is the total monthly cost, and what does it include?

If you are comparing clinics, our guide on how to vet a peptide clinic can help you spot red flags.

Footnotes

  1. Novo Nordisk. WEGOVY (semaglutide) injection and tablets: prescribing information. Revised June 2026. https://www.novo-pi.com/wegovy.pdf ↩ ↩2 ↩3 ↩4

  2. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: prescribing information. Revised August 2026. https://uspl.lilly.com/zepbound/zepbound.html ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183 ↩ ↩2

  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038 ↩

  5. Novo Nordisk. SAXENDA (liraglutide) injection: prescribing information. Revised February 2026. https://www.novo-pi.com/saxenda.pdf ↩

  6. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892 ↩

  7. Theratechnologies. EGRIFTA WR (tesamorelin) for injection: prescribing information. Revised March 2025. FDA Reference ID 5557578. ↩ ↩2

  8. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026;395(18):1781-1793. https://doi.org/10.1056/NEJMoa2604169 ↩

  9. U.S. Food and Drug Administration. Warning letter 735063 to a Sarasota, Florida peptide seller. August 24, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026 ↩ ↩2

  10. Li J, Kneeream E, Mathew B, et al. FDA evaluation of AOD-9604-related bulk drug substances. U.S. Food and Drug Administration; memo dated November 5, 2024. https://www.fda.gov/media/183584/download ↩

  11. Li J, Poon N-L, Asante K, et al. FDA evaluation of MOTS-c-related bulk drug substances. U.S. Food and Drug Administration; memo dated May 11, 2026. https://www.fda.gov/media/193347/download ↩

  12. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725 ↩

  13. Kow CS, Thiruchelvam K, Ramachandram DS, et al. Weight regain trajectories after discontinuation of semaglutide or tirzepatide: a reconstructed aggregate-data Bayesian longitudinal meta-analysis. Endocrinol Diabetes Metab. 2026;9(5):e70325. https://doi.org/10.1002/edm2.70325 ↩

  14. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. https://doi.org/10.1111/dom.15728 ↩ ↩2

  15. Novo Nordisk. NovoCare: price your Wegovy. Accessed November 12, 2026. https://www.novocare.com/obesity/products/wegovy.html ↩

  16. Eli Lilly and Company. LillyDirect: Zepbound. Accessed November 12, 2026. https://www.lilly.com/lillydirect/zepbound ↩

  17. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. Page last modified July 13, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge ↩

  18. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of April 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize ↩

  19. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↩

Frequently asked questions

Which peptides have the strongest evidence for weight loss?

Semaglutide, tirzepatide and liraglutide. All three are FDA-approved for long-term weight management in certain adults and were tested in large trials. Retatrutide had strong results in 2026 trials but is not approved. AOD-9604 and MOTS-c have little or no good human evidence.

Do I need a prescription?

Yes. The approved weight-loss medicines are prescription drugs. FDA has warned sellers that products labeled 'for research use only' and marketed for people are unapproved drugs.

What happens if I stop taking a weight-loss medicine?

On average, people regain weight after stopping. In one semaglutide study, people regained about two-thirds of the weight they had lost within a year. Plan for the long term with a provider before you start.

Is compounded semaglutide or tirzepatide the same as the brand-name drug?

No. Compounded drugs are not FDA-approved, and FDA has received reports of side effects with them, including dosing mistakes. The shortages that allowed wide compounding of these drugs have ended.

What do these medicines cost without insurance?

As of November 2026, the makers of Wegovy and Zepbound list cash prices from about $149 to $699 a month, depending on the drug, dose and refill timing. Prices and offers change often.

Questions? Talk to a licensed provider

See a free list of top rated clinics in Lakeland and Polk County, with their phone numbers and Google reviews. No one will call you.

Find a top rated provider
Find a top rated provider today